Navicixizumab, CAS 1638338-43-8

Product Description: Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. /[2]Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. /[3]Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.

CAS Number: 1638338-43-8

Molecular Weight: N/A

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Notch

• Artikelnummer: MEXHY-P99377-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99377-1
• Green Labware: Nein
• Verpackungseinheit: 1mg
• Mengeneinheit: STK